자동주사기 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측, 제품별, 적응증별, 최종사용자별, 지역별, 경쟁별(2020-2030년)

The Global Autoinjectors Market was valued at USD 9.15 Billion in 2024 and is projected to reach USD 20.43 Billion by 2030, growing at a CAGR of 14.28%. Autoinjectors are advanced drug delivery devices designed for easy and safe self-administration of medications, particularly for chronic and emergency conditions. These devices are increasingly used across therapeutic areas such as diabetes, autoimmune diseases, and anaphylaxis, offering convenience and accuracy without the need for medical supervision. The market's growth is propelled by the global shift toward patient-centric care and the rising preference for home-based treatment options. Autoinjectors improve treatment adherence through features such as ergonomic designs, concealed needles, and pre-measured doses. As healthcare systems emphasize value-based care, autoinjectors are gaining traction for reducing hospital dependency and enhancing clinical outcomes. The market also benefits from pharmaceutical innovation focused on pairing biologics with user-friendly delivery systems, supporting the trend of self-managed therapies and broadening the adoption of autoinjectors globally.

Key Market Drivers

Rising Prevalence of Chronic and Autoimmune Diseases

The growing incidence of chronic and autoimmune diseases is a primary factor driving demand for autoinjectors. Conditions such as diabetes, rheumatoid arthritis, and multiple sclerosis are on the rise due to aging populations, lifestyle changes, and better diagnostics. For example, global diabetes prevalence is expected to increase from 537 million adults in 2024 to 643 million by 2030. These conditions often require long-term injectable therapies, making autoinjectors an effective solution for regular, accurate self-administration. By minimizing the complexity of injections and reducing the need for clinic visits, autoinjectors help patients maintain consistent treatment schedules, thereby improving health outcomes and adherence. Their ease of use also reduces the risk of dosage errors and needle anxiety. As healthcare systems aim to reduce costs and improve quality through better disease management, autoinjectors have become integral to chronic care strategies, further strengthening their market growth.

Key Market Challenges

High Manufacturing and Development Costs

Developing and producing autoinjectors involves significant investment due to their design complexity and regulatory requirements. These devices must meet stringent safety, compatibility, and performance standards, particularly when paired with biologics. Processes such as stability testing, risk analysis, and ensuring device-drug integration contribute to high R&D expenditures. Smaller pharmaceutical and biotech firms without in-house manufacturing capabilities often face financial barriers to market entry. Customization demands for different therapeutic areas and regions, as well as integration of digital features for monitoring, further increase development costs. These challenges are especially pronounced in developing regions where pricing pressure limits widespread adoption. The capital-intensive nature of the autoinjector segment remains a major constraint on scalability and profitability for emerging market players.

Key Market Trends

Shift Toward Home-Based and Self-Administered Treatment Models

A key trend transforming the autoinjectors market is the growing emphasis on home-based healthcare. Patients managing long-term conditions are increasingly seeking alternatives to frequent clinical visits. Autoinjectors support this shift by allowing individuals to self-administer medication safely and efficiently. Their user-friendly design, automatic needle retraction, and preset dosing mechanisms reduce the risk of misuse and improve adherence. This aligns with healthcare strategies aimed at lowering costs, reducing hospital load, and empowering patients. Pharmaceutical companies are responding by developing drugs compatible with autoinjector formats, thereby extending product lifecycles and enhancing market reach. As patient education and digital health adoption grow, autoinjectors are poised to become a standard component of modern chronic disease management and at-home care models.

Key Market Players

• Eli Lilly and Company
• SHL Medical AG
• AbbVie Inc
• Amgen Inc
• Owen Mumford Limited
• Ypsomed AG
• Teva Pharmaceutical Industries Ltd
• Biogen Inc.
• Viatris Inc
• Pfizer, Inc.
• Gerresheimer AG

Report Scope:

In this report, the Global Autoinjectors Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Autoinjectors Market, By Product:

• Disposable Auto-injectors
• Reusable Auto-injectors

Autoinjectors Market, By Indication:

• Rheumatoid Arthritis
• Multiple Sclerosis
• Diabetes
• Anaphylaxis
• Other

Autoinjectors Market, By End User:

• Homecare Settings
• Hospitals & Clinics
• Ambulatory Surgical Centers

Autoinjectors Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Autoinjectors Market.

Available Customizations:

Global Autoinjectors Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Autoinjectors Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Disposable auto-injectors, Reusable auto-injectors {Prefilled, Empty})
  • 5.2.2. By Indication (Rheumatoid Arthritis, Multiple Sclerosis, Diabetes, Anaphylaxis, Other)
  • 5.2.3. By End User (Homecare Settings, Hospitals & Clinics, Ambulatory Surgical Centers)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Autoinjectors Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Indication
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Autoinjectors Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Indication
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Autoinjectors Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Indication
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Autoinjectors Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Indication
      • 6.3.3.2.3. By End User

7. Europe Autoinjectors Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Indication
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Autoinjectors Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Indication
      • 7.3.1.2.3. By End User
  • 7.3.2. United Kingdom Autoinjectors Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Indication
      • 7.3.2.2.3. By End User
  • 7.3.3. Italy Autoinjectors Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Indication
      • 7.3.3.2.3. By End User
  • 7.3.4. France Autoinjectors Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Indication
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Autoinjectors Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Indication
      • 7.3.5.2.3. By End User

8. Asia-Pacific Autoinjectors Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Indication
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Autoinjectors Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Indication
      • 8.3.1.2.3. By End User
  • 8.3.2. India Autoinjectors Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Indication
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Autoinjectors Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Indication
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Autoinjectors Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Indication
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Autoinjectors Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Indication
      • 8.3.5.2.3. By End User

9. South America Autoinjectors Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Indication
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Autoinjectors Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Indication
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Autoinjectors Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Indication
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Autoinjectors Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Indication
      • 9.3.3.2.3. By End User

10. Middle East and Africa Autoinjectors Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Indication
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Autoinjectors Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Indication
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Autoinjectors Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Indication
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE Autoinjectors Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Indication
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Autoinjectors Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Eli Lilly and Company
  • 14.1.1. Business Overview
  • 14.1.2. Product & Service Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Financials (If Listed)
  • 14.1.5. Key Personnel
  • 14.1.6. SWOT Analysis
• 14.2. SHL Medical AG
• 14.3. AbbVie Inc
• 14.4. Amgen Inc
• 14.5. Owen Mumford Limited
• 14.6. Ypsomed AG
• 14.7. Teva Pharmaceutical Industries Ltd
• 14.8. Biogen Inc.
• 14.9. Viatris Inc
• 14.10.Pfizer, Inc.
• 14.11.Gerresheimer AG

15. Strategic Recommendations

16. About Us & Disclaimer